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Abstract
Introduction: Primary hepatic carcinoid tumours (PHCTs) are extremely rare neuroendocrine
neoplasms. Only 58 cases have been reported in the literature and less than 10 cases were
functional.
Case presentation: We present a case of a 65 years old, Caucasian female with a large
unresectable primary hepatic carcinoid tumor secreting 5-hydroxyindoleacetic acid (5-HIAA),
presented with flushing and diarrhoea and treated with trans-catheter arterial embolization (TACE)
and subsequent administration of lanreotide (long acting somatostatin analogue).
Conclusion: The diagnosis of PHCTs is difficult due to their common radiologic characteristics
with other liver lesions. Their diagnosis is based on the exclusion of other sites of disease and the
histologic confirmation. Although the mainstay of treatment when is technically feasible is surgical
resection with optimal 5-year survival and low recurrence rate, in cases of unresectable disease
palliation with combination of TACE and administration of somatostatin analogues have good
results in controlling the disease and the patients symptoms.
Introduction
Carcinoid tumours are of neuroendocrine origin, well-dif-
ferentiated low-grade malignant neoplasms. They follow
an indolent course in comparison with other malignant
neuroendocrine carcinomas, which display varying
degrees of pleomorphism, mitotic activity, vascular inva-
sion, and necrosis [1]. Nonetheless, carcinoid tumours
can be quite unpredictable and may cause carcinoid syn-
drome [2]. They occur most frequently in the gastrointes-
tinal tract and the respiratory system and they frequently
metastasize to the liver [3-5]. Primary hepatic carcinoid
tumours (PHCTs) are rare with only 58 cases described in
the literature since the first report in 1958 by Edmondson
[6]. The rarity of PHCT makes it difficult for clinicians to
suspect and diagnose it precisely. Although PHCT shows
a slow growth, surgical resection is the treatment of
choice. In case of unresectability due to anatomical rea-
sons TACE and long acting somatostatin analogues (SSAs)
can stabilize the disease and provide long term palliation.
Case presentation
A 65 years old, Caucasian female patient presented on
admission to our Liver Surgical Unit with a history of
flushing, diarrhoea, vomiting and low grade fever. Ultra-
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both liver lobes. Computed Tomography (CT) revealed
heterogeneous hypodense lesions invading most of the
hepatic parenchyma. The lesions showed mild gradual
enhancement during the arterial and portal phases, while
cystic areas were also demonstrated. The larger of the
lesions showed extrahepatic extension compressing and
dislocating the duodenum. No vascular invasion was
noted (fig. 1a, b). A 24 h-urine 5-hydroxyindoleacetic acid
(5-HIAA) level was high (36,4 mg/day – normal range: 1–
6 mg/day); the tumor markers CEA and Ca 19-9 were
within normal range. The patient underwent a CT-guided
biopsy of the larger lesion and the histology revealed a
well differentiated tumor, composed of solid (insular)
nests or ribbons of monomorphic, medium-sized cells,
with variably eosinophilic neoplasm and round nuclei.
Peripheral palisading was also noted in some solid nests
(fig. 2) with no tumor necrosis. The morphologic features
of the tumor were compatible with a neuroendocrine
tumor. The diagnosis was confirmed by immunohisto-
chemistry. The neoplastic cells were proven to be positive
for the endocrine markers Chromogranin A, Synapto-
physin, NSE and CD56, in addition to Cytokeratins Cam
5.2, 5/6 and 19 (fig. 3a, b). No immunohistochemical
findings were suggestive for carcinomatous (metastatic or
primary) or metastatic melanocytic growth identified.
In addition to these diagnostic modalities the patient
underwent an abdominal and chest CT scan along with
abdominal MRI, mammography and an upper and lower
GI endoscopy which didn't reveal the primary. A total
body octreoscan with In111, a MIBG scan and a [11C]
5HTP-PET showed intense uptake of the radiotracer exclu-
sively in the liver. Based on the biochemical and thorough
radiological investigation, the diagnosis of PHCT was
made with certainty. Due to the extended liver invasion,
Contrast enhanced CT, arterial (a) and portal venous phases (b): many lesions are demonstrated in both liver lobes showing progressive co trast enhancementFigu  1
Contrast enhanced CT, arterial (a) and portal venous phases (b): many lesions are demonstrated in both liver lobes showing 
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with TACE and subsequent administration of lanreotide
(long acting somatostatin analogue) 30 mg/28 days sub-
cutaneous for 22 months. TACE included streptozotocin
1.5 g/m2 dissolved in 10 ml of normal saline (0,9%) com-
bined with 10 ml of lipiodol. The emulsion was injected
into the branches of the hepatic artery distal to the origin
of gastro-duodenal artery. Two years later the patient is
free of symptoms with no radiologic disease progression.
Discussion
Carcinoid tumors are rare, slowly growing neuroendo-
crine neoplasms that account for only 2% of all gastroin-
testinal tumors [7]. PHCTs are extremely rare neoplasms
reported infrequently. PHCTs are detected incidentally
and occur usually in patients older than 50 years and
slightly more often in females. They show a slow growth
and in most cases they are non-functional [5,8].
Their histogenesis hasn't been clarified. It is hypothesized
that they arise from scattered neuroendocrine cells in the
intrahepatic biliary epithelium. Another possible explana-
tion is that chronic inflammation in the biliary system
may predispose to the development of neuroendocrine
tumor by initiating intestinal metaplasia or even that
these tumors originate from heterotopic pancreatic or
adrenal tissue, mainly in the central part or perihilar areas
of the liver, where heterotopic pancreatic tissue is most
often located. However, the clinician must be aware of the
possibility that an apparent PHCT might be a metastatic
one of a primary tumor that remains obscure despite an
extensive assessment.
Diagnosis of primary hepatic carcinoid tumors is difficult
as the radiologic appearance on ultrasound, CT, and MRI
can mimic hepatocellular carcinoma, cholangiocarci-
noma and metastases of unknown origin. A solid mass
with cystic areas and hyperechoic or mixed pattern is a
common finding detected by ultrasound. In addition cal-
cifications are sometimes demonstrated along the margin
of the cysts. Of note they are markedly hypervascular on
contrast-enhanced US with significant enhancement [9].
Contrast enhanced CT permits a comprehensive dynamic
study of neuroendocrine liver lesions. Small carcinoids
are enhanced homogeneously in the arterial phase, while
large tumors usually show a peripheral pattern of
enhancement. In late phases most lesions evolve into low
density masses, but progressive enhancement has also
been described and presumably corresponds to prolifera-
tive fibrous tissue inside the lesion [10]. On MRI primary
carcinoids usually present with low intensity in T1-w and
high intensity on T2 images.
Intra-lesion solid components are enhanced in the early
arterial phase in a similar fashion with hepatocellular car-
cinoma. After the administration of a specific liver con-
trast (super paramagnetic iron oxide) the extent of the
tumor is more clearly delineated due to the decrease of
normal liver parenchyma signal intensity [11]. On angiog-
raphy the characteristic hypervascularity is evident with or
without staining. Nowadays with the evolution of CT or
MR angiography, interventional diagnostic studies could
not be considered as first line examinations. However, we
can not depend on cross-sectional imaging modalities for
accurate diagnosis, due to overlapping imaging features
Liver carcinoidFigure 2
Liver carcinoid. Typical morphology of low-grade endocrine 
tumor showing insulinar arrangement of medium-sized cells 
with round nuclei and peripheral palisading. The stroma is 
vascular and fibrotic. E/H × 400.
(a) Strong immunopositivity for chromogranin A. PAP × 200Figu e 3
(a) Strong immunopositivity for chromogranin A. PAP × 200. 
(b) Strong immunopositivity for synaptophysin. PAP × 200.
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Although specific liver contrast agents are helpful in the
diagnosis of PHCTs, liver biopsy is warranted to exclude
other more common lesions. Tumor cells usually stain
positive with chromogranin, synaptophysin and neuron-
specific enolase. Octreoscan is a valuable tool, permitting
not only accurate diagnosis of neuroendocrine tumors but
also excluding small metastatic deposits in bones or
lymph nodes, which CT or MRI fail to detect [12]. PET
scan has been recognized as a useful tool in visualization
of neuroendocrine tumors (NET) that lack somatostatin
receptor type 2 and are negative on somatostatin receptor
scintigraphy (SRS). In our case combined with SRS and
MIBG, [11C] 5HTP-PET demonstrated the primary nature
of liver carcinoid.
It appears that most PHCTs are functionally silent. Presen-
tation with abdominal distension and discomfort is most
common, and carcinoid syndrome is rare although is doc-
umented in our case. This is the second case reported in
the literature of carcinoid syndrome related to PHCT and
proved by abnormal HIAA urine levels.
The mainstay of treatment of primary hepatic carcinoid
tumor is liver resection. In the literature up to 85% of
patients with PHCT have resectable disease [13]. When
PHCT is confined to a single lobe, surgical resection
should be taken into consideration, and a postoperative
5-year survival rate of 74% has been reported, with a
recurrence rate of 18% [8]. Whether bilateral non resecta-
ble lesions exist, palliative cyto-reductive surgery in com-
bination with TACE might be effective [14]. TACE has
been reported to be effective in terms of temporary con-
trol of the disease or prolongation of free disease survival
in selective patients [15]. The role of somatostatin ana-
logues is well defined regarding stabilization of the meta-
static neuroendocrine disease and control of symptoms.
However the efficacy of SSAs as a treatment option for
PHCT is not well defined. In our single case the combina-
tion of TACE with lanreotide was helpful to offer long
term palliation.
Conclusion
PHCTs represent a rare entity difficult to diagnose by the
conventional radiology studies. Exclusion of another pri-
mary and liver biopsy is strongly warranted. The natural
history of these lesions is long and a median survival of
several years has been reported for patients who have been
treated by resection. TACE with long acting somatostatin
analogues might be helpful to offer long term palliation.
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